Direct Rx FDA Inspection Record

FEI 3011690045 · Inspections, Form 483s, warning letters and import refusals

Direct Rx is an FDA-registered facility (FEI 3011690045) located in Dawsonville, GA, US. Registered operations: RELABEL; REPACK. RegDataLab tracks 3 FDA inspections at this facility.

What FDA found at this site

Latest inspection
Jun 4, 2026: No Action Indicated (NAI)
Inspections on record
3 (1 VAI, 2 NAI)
Last OAI inspection
None on record
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
21, latest Sep 29, 2026

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Jun 4, 2026No Action Indicated (NAI)No citations listed
Dec 15, 2017No Action Indicated (NAI)Returned drug products identified and held (21 CFR 211.204)
Aug 13, 2015Voluntary Action Indicated (VAI)SOPs not followed / documented (21 CFR 211.100(b))
Prepared for each batch, include complete information (21 CFR 211.188)
Written warehousing procedures established/followed (21 CFR 211.142)

Recalls

Showing the 10 most recent of 21 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Sep 29, 2026Class IID-0107-2027Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Direct Rx…
Subpotent Drug
Jun 22, 2026Class IID-0617-2026DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60…
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Mar 7, 2025Class IID-0567-2025Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by… and 1 more product
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Jan 31, 2025Class IID-0364-2025CIPROFLOXACIN OPHTH SOLUTION, 0.3% 5mL bottle, Rx Only, Generic for CILOXAN, Packaged and…
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Aug 9, 2024Class IID-0041-2025Ibuprofen 800mg, Generic for: Motrin, Each tablet contains: Ibuprofen, USP 800 mg…
Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.
Mar 22, 2023Class IID-0507-2023Alprazolam C-IV, 0.5 mg, 30 Tabs per bottle, Rx only, Packaged and Distributed By: Direct… and 2 more products
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Mar 13, 2023Class IID-0476-2023Montelukast Sodium Tablets, USP, 10 mg Tablets, Rx Only, Packaged as: a) 30-count bottle… and 10 more products
cGMP deviations
Nov 2, 2022Class IID-0101-2023Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct…
cGMP deviation: discontinue of stability support for product.
Sep 12, 2022Class IID-1535-2022Triamcinolone Acetonide cream, 0.1%, 80 g tube, Rx only, Packaged and Distributed By…
CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.
May 13, 2022Class IID-0888-2022Zonisamide Capsules USP, 100 mg, 90-count bottle, Rx Only, Packaged and Distributed By…
CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory.

FDA record score

48 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 16, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

22 records behind this number
RecordDatePoints x age weightAdds
Class II recall D-0107-2027, this FEI as the recalling firmSep 29, 20264 x 14
Class II recall D-0617-2026, this FEI as the recalling firmJun 22, 20264 x 14
Class II recall D-0567-2025, this FEI as the recalling firmMar 7, 20254 x 14
Class II recall D-0364-2025, this FEI as the recalling firmJan 31, 20254 x 14
Class II recall D-0041-2025, this FEI as the recalling firmAug 9, 20244 x 0.62.4
Class II recall D-0507-2023, this FEI as the recalling firmMar 22, 20234 x 0.62.4
Class II recall D-0476-2023, this FEI as the recalling firmMar 13, 20234 x 0.62.4
Class II recall D-0101-2023, this FEI as the recalling firmNov 2, 20224 x 0.62.4
Class II recall D-1535-2022, this FEI as the recalling firmSep 12, 20224 x 0.62.4
Class II recall D-0888-2022, this FEI as the recalling firmMay 13, 20224 x 0.62.4
Class II recall D-0893-2022, this FEI as the recalling firmMay 11, 20224 x 0.62.4
Class II recall D-0971-2022, this FEI as the recalling firmMay 5, 20224 x 0.62.4
Class II recall D-0650-2022, this FEI as the recalling firmMar 4, 20224 x 0.62.4
Class II recall D-0637-2022, this FEI as the recalling firmFeb 17, 20224 x 0.62.4
Class II recall D-0714-2022, this FEI as the recalling firmDec 7, 20214 x 0.62.4
Class II recall D-0829-2021, this FEI as the recalling firmSep 14, 20214 x 0.251
Class II recall D-0300-2021, this FEI as the recalling firmMar 2, 20214 x 0.251
Class II recall D-0058-2021, this FEI as the recalling firmOct 12, 20204 x 0.251
Class II recall D-0016-2021, this FEI as the recalling firmJan 15, 20204 x 0.251
Class II recall D-0018-2021, this FEI as the recalling firmApr 30, 20194 x 0.251
Class II recall D-0032-2021, this FEI as the recalling firmMar 12, 20194 x 0.251
Inspection classified VAIAug 13, 201510 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Direct Rx as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Direct Rx yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Direct Rx
Location
Dawsonville, GA (US)
Registration Expires
Dec 31, 2027
Operations
RELABEL; REPACK
Source
decrs

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.